Northland Securities Sticks to Their Buy Rating for Cryolife

Northland Securities analyst Suraj Kalia maintained a Buy rating on Cryolife (NYSE: CRY) yesterday and set a price target of $23.50. The company’s shares opened today at $24.05, close to its 52-week high of $24.45.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 8.3% and a 60.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Tactile Systems Technology, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Cryolife is Moderate Buy and the average price target is $25.75, representing a 7.1% upside.

In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $28 price target.

Find more picks by Best Performing Analysts >>

Cryolife’s market cap is currently $873.2M and has a P/E ratio of 241. The company has a book value ratio of 3.1516.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.